Background
==========

In post-marketing surveillance, often questions arise about characteristics of the patient group for which a drug is indicated, such as the age distribution and co-morbidities to be expected \[[@B1],[@B2]\]. Therapeutic risk management involves an understanding of characteristics specific to a group of patients for whom a drug will be prescribed. Often, some safety issues of a new product are predictable; however after market introduction in practice often adverse events are reported that were not foreseen \[[@B3],[@B4]\]. A description of all co-morbidities seen in the target population would help better understand the patient population and thus, provide some context for new safety issues.

Referring to Risk Management Plans (RMPs) submitted to regulatory authorities, a guide on pharmacovigilance published by the Medicines and Healthcare products Regulatory Agency in the UK comments that some RMPs tend to focus on what is already known rather than identifying the areas in which information is lacking \[[@B5]\]. It was also noted that the relevance of the epidemiology of the disease to the target indication is often not sufficiently considered.

To help address these issues, data on large groups from the general population are needed. Increasingly in the past years, health-care databases have become available that enable the study of large numbers of patients with follow-up data. The US Food and Drug Administration Amendment Act of 2007 (FDAAA) called for the establishment, under the auspices of an independent foundation, of a set of databases of health insurance claims data for 100 million people by 2012 \[[@B6],[@B7]\]. Thus, data on sufficient numbers of patients are becoming more available to better understand the co-morbidities in groups or subgroups of patients with a target disease.

Listing co-morbidities, rank-ordered by prevalence, will show various conditions associated with the disease of interest; these associations may be either known, or not yet established. Additionally, such data on a patient group will reflect the target group for a product. The target indication is often restricted by criteria relating to severity of disease or by treatments given earlier. While healthcare databases usually do not have sufficient data on stage or severity of a specific disease, prescribed medication is usually well covered. A subgroup within a healthcare database can be selected, identified by disease codes and restricted by criteria on medication. Information gathered on age/sex profile, co-morbidities and co-medication of such a group should help to describe disease epidemiology specific for a target indication.

Rheumatoid arthritis is a chronic condition characterized by inflammation and modulation of immunity, affecting many organs apart from the loco-motor system. Various studies have described associations of RA with selected morbidities such as infectious conditions \[[@B8]-[@B10]\] and cardiovascular disease \[[@B11]-[@B14]\]. Because of this potential association with many conditions, it was chosen as the target condition to describe unselected co-morbidity in a data-driven way. The objective was to quantify a large number of co-morbidities associated with RA, as compared to a control group. Associations found should not be assumed to be causal; however they can provide a base for further analyses and for hypothesis testing in different data sets.

Methods
=======

Thomson\'s MarketScan Commercial Claims and Encounters Research Database and the Medicare Supplemental from January 1, 1999 through June 30, 2007 was the data source for this analysis. Marketscan is composed of claims submitted to health plans which have contracts with large private employers or with public organizations in the United States. The longitudinal database covers, at the patient level, all inpatient, outpatient, and prescription claims, as long as employees stay enrolled. It consists of employer- and health plan sourced data. Nearly 18 million individuals are included in the 2006 database: employees, their spouses, and dependents. Healthcare for these individuals is provided under a variety of fee-for-service, fully capitated (i.e. set amount per person), and partially capitated health plans. Medical claims are linked to outpatient prescription drug claims and person-level enrollment information. This is one of the largest collections of patient data in the US with over four billion patient records. It includes 77 contributing employers and 12 contributing health plans, with 126 unique carriers, and Medicaid data from eight states \[[@B15]\]; Medicaid covers individuals and families with low income and resources. Elderly are well represented, through the inclusion of groups covered by Medicare, the US social insurance program for people who are aged 65 years and over.

MarketScan research databases meet or exceed requirements of the US Health Insurance Portability and Accountability Act (HIPAA) of 1996. The MarketScan databases underwent a statistical analysis by a third party confirming that HIPAA requirements for fully de-identified data sets were met. Thus, data use met HIPAA criteria for anonymous and aggregate research analysis and reporting of data derived from clinical records not requiring specific patient consent or ethical approval.

Cases were defined as persons with at least two claims for RA \[codes ICD 9: 714.0\*, 714.1\*, 714.2\*, and 714.3\*.\] that were non-diagnostic (i.e. not blood, lab, radiological claims) with active insurance status on June 30, 2007. At least one diagnosis of RA had to be before July 1 2006 and the index date was defined as the earliest claim containing the diagnosis. The control group was patients who had at least two claims for eczema/dermatitis \[codes ICD 9: 690.\*, 691.\*,692.\*\] with the same criteria as the cases for insurance status and timing of the claims. Controls were matched 1:1 to the cases, by age, gender and health plan \[Medicare or not\] using propensity scores.

Propensity matching was done using a logistic regression model on dependent variable RA = 0,1 where 1 = in RA cohort and with explanatory variables: age, sex, and health plan (Medicare or not). The propensity score is the probability of being in the RA cohort. Then, one control was selected for each case based on a best match algorithm, using 8 digits of the probability value, then 7 digits, etc. \[[@B16]\] Each control was used only once. SAS version 8.2 was used for all analyses.

All co-morbidities with a level 5 - i.e. the most detailed - ICD9 (diagnostic) code were identified in the case and control groups in the one-year window from July 1, 2006 through June 30, 2007. A one-year period prevalence was calculated for each co-morbidity for both case and control groups. Occurrence of each co-morbidity was counted only once for each patient.

Also, a set of relative risks (RR) was calculated for patients aged at least 16 years old as of RA index date, by dividing the one-year period prevalence of each co-morbidity in the RA group with the corresponding prevalence in the controls. Thus, the RR represents here a ratio of one-year prevalences. After this, the various co-morbidities were rank-ordered by magnitude of RR; 95% confidence intervals were added.

ICD9 codes covering arthropathies and related disorders \[710-719\], dorsopathies \[720-724\] and rheumatism, excluding the back \[725-729\] were excluded from the analysis (as likely related/part RA), also mechanical complications of internal orthopedic device, implant and graft \[996.4\]. In order to obtain stable estimates, rank-ordering was done for non-rare diagnoses (occurring in at least 20 persons in control group).

Results
=======

Records for 62,681 persons with RA were selected (all ages). Mean age was 59.0 Y, with 73.8% female, 35% Medicare-covered. A total of 6,897 different ICD9 diagnostic codes were recorded in this group, of which 2,220 occurred in 20 or more persons with RA.

The most prevalent co-morbidities in the cohort with RA are listed in Table [1](#T1){ref-type="table"}. At the more detailed level of the ICD9 classification (level 5), the most commonly registered co-morbidities were hypertension not otherwise specified (NOS) (20.4%), benign hypertension (19.9%), chest pain NOS (13.9%), and hyperlipidemia not elsewhere classified (NEC)/NOS (13.9%).

###### 

Most common co-morbidities in cohort with rheumatoid arthritis (N = 62,681, all ages)\*

  Condition (ICD-9 code)                            Number of persons   Percent
  ------------------------------------------------- ------------------- ---------
  4019 Hypertension NOS                             12,773              20.4%
  4011 Benign hypertension                          12,482              19.9%
  78650 Chest pain NOS                              8,742               13.9%
  2724 Hyperlipidemia NEC/NOS                       8,690               13.9%
  25000 Diabetes Mellitus II without complication   7,504               12.0%
  78079 Malaise & fatigue NEC                       6,046               9.6%
  5990 Urinary tract infection NOS                  5,965               9.5%
  78900 Abdominal pain unspecified site             5,712               9.1%
  7862 Cough                                        5,649               9.0%
  2449 Hypothyroidism NOS                           5,524               8.8%
  78605 Shortness of breath                         5,516               8.8%
  4660 Acute bronchitis                             5,400               8.6%
  2720 Pure hypercholesterolemia                    5,046               8.1%
  4619 Acute sinusitis NOS                          4,833               7.7%
  2859 Anemia NOS                                   4,632               7.4%
  73300 Osteoporosis NOS                            4,529               7.2%
  41401 Coronary atherosclerosis native vessel      4,325               6.9%
  53081 Esophageal reflux                           4,288               6.8%
  7020 Actinic keratosis                            4,249               6.8%
  73390 Bone & cartilage disease NOS                4,113               6.6%
  4659 Acute upper respiratory infection NOS        4,112               6.6%
  496 Chronic airway obstruct NEC                   4,041               6.4%
  36616 Senile nuclear cataract                     3,914               6.2%
  78609 Respiratory abnormality NEC                 3,605               5.8%
  7840 Headache                                     3,246               5.2%
  41400 Coronary atherosclerosis unspec. vessel     3,002               4.8%

\* Excluded arthritis/RA-related codes ICD 710-729; 996.4.

NOS: Not otherwise specified NEC: Not elsewhere classified

A total of 61,591 persons with RA were aged at least 16 years and subsequently matched with the control group. Demographic distribution for RA cases is shown in Figure [1](#F1){ref-type="fig"}. The demographic distribution of the controls was identical. Co-morbidities strongly associated with RA in the case group compared to controls are shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. A full set of co-morbidities is provided in additional File [1](#S1){ref-type="supplementary-material"}: Rank-ordered relative risks of co-morbidities in patients with rheumatoid arthritis.
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###### 

Top 30 Relative risks of co-morbidities in patients with rheumatoid arthritis 16 years and older as compared with control group (N = 61,591 for each group)

  ICD9    Co-morbidity Condition                                                                Persons with RA (N)   Percent   RR         95% CI
  ------- ------------------------------------------------------------------------------------- --------------------- --------- ---------- -----------
  6960    Psoriatic arthropathy                                                                 1,540                 2.5%      **12.3**   10.5-15.1
  99529   Adverse effect medicinal and biologic substance NEC/NOS                               360                   0.6%      **7.7**    5.7-10.4
  99666   Reaction-internal joint prosthesis                                                    131                   0.2%      **4.0**    2.7-5.8
  9952    Unspecified adverse effect drug, medicinal and biol substance properly administered   717                   1.2%      **3.9**    3.4-4.7
  73309   Osteoporosis NEC                                                                      479                   0.8%      **3.9**    3.2-4.8
  5163    Idiopathic fibrosing alveolitis                                                       205                   0.3%      **3.9**    2.9-5.2
  73027   Osteomyelitis NOS-ankle                                                               148                   0.2%      **3.5**    2.5-5.0
  2793    Immunity deficiency NOS                                                               81                    0.1%      **3.4**    2.1-5.3
  7901    Elevated sediment rate                                                                171                   0.3%      **3.3**    2.4-4.5
  7955    Tuberculin test reaction abnormal or positive                                         239                   0.4%      **3.3**    2.5-4.3
  99520   Adverse effect medicinal and biologic substance NOS                                   708                   1.1%      **3.2**    2.8-3.8
  73020   Osteomyelitis NOS-unspec                                                              119                   0.2%      **3.1**    2.2-4.5
  28529   Anemia-of other chronic illness                                                       415                   0.7%      **3.1**    2.6-3.8
  2550    Cushing\'s syndrome                                                                   61                    0.1%      **3.0**    1.8-5.1
  515     Postinflammatory pulmonary fibrosis                                                   1,221                 2.0%      **3.0**    2.7-3.4
  2841    Pancytopenia                                                                          80                    0.1%      **3.0**    1.9-4.6
  4920    Emphysematous BLEB                                                                    72                    0.1%      **2.9**    1.8-4.5
  79579   Other and unspecified nonspecific immunologic findings                                373                   0.6%      **2.8**    2.3-3.5
  2794    Autoimmune disease NEC                                                                142                   0.2%      **2.8**    2.1-3.9
  5369    Stomach function disorder NOS                                                         67                    0.1%      **2.8**    1.8-4.4
  4430    Raynaud\'s syndrome                                                                   251                   0.4%      **2.8**    2.2-3.5
  53130   Acute stomach ulcer NOS                                                               76                    0.1%      **2.7**    1.8-4.2
  70709   Decubitus ulcer, site NEC                                                             97                    0.2%      **2.7**    1.8-4.0
  8082    Fracture of pubis-closed                                                              136                   0.2%      **2.7**    1.9-3.7
  27549   Disorders of calcium metabolism NEC                                                   69                    0.1%      **2.6**    1.7-4.2
  73340   Aseptic necrosis bone NOS                                                             75                    0.1%      **2.6**    1.7-4.0
  8088    Pelvic fracture NOS-closed                                                            121                   0.2%      **2.6**    1.8-3.6
  73007   Acute osteomyelitis-ankle                                                             77                    0.1%      **2.6**    1.7-3.9
  4476    Arteritis NOS                                                                         247                   0.4%      **2.5**    2.0-3.2
  73302   Idiopathic osteoporosis                                                               182                   0.3%      **2.5**    1.9-3.3

\* Aged at least 16 years, matched controls with Dermatitis/Eczema diagnosis.

Only includes conditions for which there were at least 20 controls Excluded Arthritis/RA-related codes ICD 710-729;996.4.

NOS: Not otherwise specified NEC: Not elsewhere classified
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Additional file [2](#S2){ref-type="supplementary-material"} shows top 30 of relative risks as well as odds ratios of co-morbidities in patients with RA; comparator group had dermatitis/eczema diagnosis

Additional file [3](#S3){ref-type="supplementary-material"} shows same analysis as additional file [2](#S2){ref-type="supplementary-material"}, however with a different (random) comparator group.

Strong associations with RA (RR \> 3) were found for psoriatic arthropathy, adverse effect to medicine/biological, reaction to internal joint prosthesis, unspecified adverse effect, osteoporosis, idiopathic fibrosing alveolitis, osteomyelitis, immune deficiency, elevated sedimentation rate, tuberculin test reaction, anemia and Cushing syndrome \[Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}\]. As described in the Methods section, a set of ICD codes covering conditions of the loco-motor system was excluded from the analysis. All RRs in Table [2](#T2){ref-type="table"} were statistically significant. The full set of co-morbidities as shown in additional File [1](#S1){ref-type="supplementary-material"} includes many with a RR \< 1, i.e. associated with the control group. Many of these are skin conditions.

Discussion
==========

Data on a large number of patients (\> 60,000) with a diagnosis of rheumatoid arthritis were available, with a large number (\> 6,000) of different ICD9 diagnostic codes. Most prevalent co-morbidities were in the cardiovascular area: hypertension, chest pain and hyperlipidemia. The rank-ordering of relative risks shows a variety of conditions to be associated with RA. Some of these have been reported previously such as fibrosing alveolitis \[[@B17],[@B18]\] and acute stomach ulcer \[[@B19],[@B20]\]; it also shows a strong and statistically significant association with osteomyelitis. Published studies on even relatively large cohorts of RA patients typically show only a few cases of this rare but severe infection. \[[@B21]-[@B23]\]. Also, of note, is the strong association found with \'adverse effect to medication\'; this is an ICD-9 category with no information on the nature of the reaction or the product imputed. RR for osteoporosis is markedly increased, also for various fractures; this is in line with the findings of Van Staa et al based on the General Practice Research Database in the UK \[[@B24]\]. Osteoporosis is likely a direct consequence of RA, decreased physical activity and treatments with corticosteroids \[[@B25]\]. The association of RA with psoriatic arthropathy may be a consequence of similarities of signs of these conditions in their early stages where follow-up of patients would lead to a change of diagnosis. Psoriatic arthropathy is in the ICD category of skin conditions; hence it was included in Table [2](#T2){ref-type="table"}. The many diagnostic codes that are part of ICD categories that cover arthritis and other conditions of the locomotor system have been excluded as these were not the focus of the co-morbidity analysis. However these are included in additional File [1](#S1){ref-type="supplementary-material"}: Rank-ordered relative risks of co-morbidities in patients with rheumatoid arthritis.

All RRs shown in Table [2](#T2){ref-type="table"} are statistically significant with lower boundaries of the 95% confidence interval above 1. This is a result of conditions being both strongly associated with RA and not too rare (at least 20 cases in control group).

It should be stressed that some less common events may be highly relevant from a drug safety perspective. A data set covering information on patients with RA or any other condition may indeed be used for analysis of any event of interest, irrespective of its rate of occurrence.

The control group included a group of patients with a non-systemic chronic condition (eczema/dermatitis) occurring in a broad age range, but with no direct relation to RA.

The choice of a control group of patients with another chronic condition should help to control for bias in detecting co-morbidities as both groups have exposure to health care. It should be noted however that some diagnoses that are relatively common both in the general population and in the RA population such as various skin conditions have a RR under 1 due to an association with the control group. For example \'pruritic disorders NOS\' had a RR of 0.40.

Various control groups may be selected, depending on the types of outcomes of interest. For example, some diagnoses are typically made in the setting of out-patient clinics, other ones during hospital stays. The choice of control groups should take these differences into account.

As with any data source, claims data have limitations which are due both to the nature of administrative claims for payment purposes and convenience samples as opposed to random samples of the population. As such, they may contain biases or fail to generalize well to other populations. Clinical knowledge about comorbidities of RA or eczema/dermatitis is likely to drive the conditions that clinicians test for and deem worth recording. Information on important aspects such as smoking behaviour and ethnicity is missing. Associations found should not be considered to be causal. Rank-ordering of RRs of diagnostic codes is a tool to quickly identify characteristics specific to patients with a condition of interest. This can be applied to various subgroups of patients with the condition selected such as patients treated with different pharmaceutical products of interest. Comparisons of such groups can show whether products are prescribed to patients with different co-morbidity patterns prior to treatment. Understanding such selective prescribing can help in the interpretation of reported adverse effects of new products, as a part of good risk management practice.

Conclusions
===========

Rank-ordering of relative risks of diagnostic codes is a tool to quickly identify co-morbidities specific to a patient group of interest, in this case patients with rheumatoid arthritis. Conditions with a strong (RR \> 3), statistically significant association with RA included osteomyelitis; the large cohort of RA patients (\> 60,000) covered makes it possible to quantify risk for this and other uncommon co-morbiditities.
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